Silver Lake Enters Into Exclusive Negotiations to Acquire Groupe Meilleurtaux
Groupe Meilleurtaux (“the Company”), a leading French financial services provider, Silver Lake, a global technology investment firm, and West Street Capital Partners VII (a fund managed by the Goldman Sachs Merchant Banking Division), today announced that they have entered into exclusive negotiations under which Silver Lake would acquire a majority stake in Groupe Meilleurtaux from West Street Capital Partners VII. Management would re-invest in Meilleurtaux alongside Silver Lake.
Hervé Hatt and Guillaume Autier, Chairman and CEO of Groupe Meilleurtaux, said: “We are extremely proud of what Meilleurtaux has achieved over the past three years, with the group’s revenue doubling between 2017 and 2019. Together with our outstanding team, our franchisees, and our partners, we have built a highly successful business with a strong track record of increasing transparency and access to the French financial services ecosystem. As Meilleurtaux begins its new chapter of growth, we are thrilled to welcome Silver Lake, a world-class technology investor with deep financial services and online industry expertise as well as strong value-creation capabilities, as our new majority investor. This investment marks a pivotal step for our company, and we are excited to lead it through this journey.”
Christian Lucas, Co-Head of Silver Lake EMEA, said: “Meilleurtaux is an exceptional company with a unique value proposition across its ecosystem of customers, channel partners and financial providers. We are highly impressed by the way Hervé, Guillaume and the rest of the team have strengthened the business and built it into a multi-channel financial services powerhouse with some 90 million online and mobile visits per year across its various properties. Investing in high-growth, impactful and pioneering business models is at the core of Silver Lake’s DNA, and the privilege of partnering with this management team as Meilleurtaux enters a new phase of growth and value creation is firmly consistent with our mission.”
Michele Titi-Cappelli, Managing Director and Alexandre Flavier, Executive Director of Goldman Sachs, added: “Meilleurtaux is an outstanding platform that plays a pivotal role in democratizing transparency and consumer choice in the French financial services ecosystem. We couldn’t be more pleased with the success of Meilleurtaux under the leadership of Hervé, Guillaume and their team since 2017. We strongly believe that Meilleurtaux is still at the beginning of its growth journey.”
Founded in 1999 and headquartered in Paris, France, Groupe Meilleurtaux provides a broad and diversified range of financial services and products that started historically with mortgage loan comparison and brokerage. Its wide suite of high-quality solutions is seamlessly accessible to consumers through a comprehensive range of leading online and mobile tools including its flagship websites Meilleurtaux.com, Lecomparateurassurance.com and Meilleurplacement.com, as well as financial information website MoneyVox, which in aggregate attract an industry-leading number of approximately 90 million yearly visits. Meilleurtaux.com’s award winning and web-native digital solutions comprise a set of innovative, client-centric toolkits including intuitive financial simulators, calculators and barometers focused solely on helping households save money across their most important financial life decisions on a daily basis. The Company’s unique multi-channel offering is enabled by France’s largest network of 340 brokerage branches, offering customers an unmatched service level in partnership with an industry leading network of more than 300 established bank and insurance providers that together have shaped Meilleurtaux’s trusted brand for over two decades.
Silver Lake is planning to invest heavily in Groupe Meilleurtaux’s product range and partnership network to help further accelerate the Company’s strong organic and inorganic revenue growth across its core business of mortgage and loan insurance brokerage, as well as to further expand its leading offering across the financial services ecosystem. Silver Lake will thereby preserve Groupe Meilleurtaux’s winning operating model while leveraging its capabilities to support management in strengthening it further.
The proposed transaction is expected to close in the fourth quarter and is subject to regulatory approvals and works council information and consultation procedures.
From 1 August 2020 the Meilleurtaux Group’s leadership team will include Guillaume Autier as CEO and Thomas Kienzi as CFO, with Hervé Hatt as chairman of the Board.
About Groupe Meilleurtaux and Meilleurtaux.com
Founded in 1999 and headquartered in Paris, France, Groupe Meilleurtaux is a leading French financial services provider with a broad and diversified range of financial services including loan insurance and mortgage brokerage, debt consolidation solutions, savings & investment products as well as P&C and health insurance distribution and brokerage offerings, available both online and through France’s largest network of 340 brokerage branches. For more information, please visit meilleurtaux.com
About Silver Lake
Silver Lake is a global technology investment firm, with over $40 billion in combined assets under management and committed capital and a team of approximately 100 investment and operating professionals located in Silicon Valley, New York, London and Hong Kong. Silver Lake’s portfolio of investments collectively generates more than $230 billion of revenue annually and employs 370,000 people globally. For more information about Silver Lake and its portfolio, please visit silverlake.com.
About Goldman Sachs Merchant Banking Division
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. Goldman Sachs Merchant Banking Division (MBD) is the primary center for the firm’s long-term principal investing activity. MBD is one of the leading private capital investors in the world with investments across private equity, infrastructure, private debt, growth equity and real estate.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005830/en/
Contact information
Media contacts
FOR SILVER LAKE:
Jennifer Stroud
jennifer.stroud@edelman.com
M: +1-646-565-1792
Virginie Spelle
virginie.spelle@elanedelman.com
M: +33 (0)6 34 03 15 00
FOR GOLDMAN SACHS MERCHANT BANKING DIVISION:
Joseph Stein
+44 20 7774 2523
FOR MEILLEURTAUX.COM:
Anne-Charlotte Neau
anne-charlotte.neau@taddeo.fr
+33(0)6 23 73 56 03
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom